Congress passes BioShield bill, but some talk about BioShield II

After almost two years of disputes and delay, the House overwhelmingly approved legislation last month to fund private-sector development of vaccines and countermeasures to biological and chemical warfare. The Project BioShield bill had passed the Senate last May and provides $5.6 billion over 5 years to purchase counter-terrorism therapies for national stockpiles.